NFAT5 predesign siRNA
- Known as:
- NFAT5 predesign small interfearing RNA
- Catalog number:
- RI13569
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- NFAT5 predesign siRNA
Related genes to: NFAT5 predesign siRNA
- Gene:
- NFAT5 NIH gene
- Name:
- nuclear factor of activated T cells 5
- Previous symbol:
- -
- Synonyms:
- TONEBP, KIAA0827, NFATL1, OREBP, NFATZ, NF-AT5
- Chromosome:
- 16q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-16
- Date modifiied:
- 2019-04-23
Related products to: NFAT5 predesign siRNA
Related articles to: NFAT5 predesign siRNA
- Myasthenia gravis (MG) is an autoimmune disease driven by autoantibodies targeting the neuromuscular junction, leading to muscle weakness. Although emerging evidence implicates circular RNAs (circRNAs) in MG, their specific regulatory mechanisms remain largely unknown. In particular, the role of circNUP214 in MG has not been characterized. CircNUP214 expression in PBMCs and CD4 T cells from MG patients and healthy controls was determined by qRT-PCR. Its circular structure and cytoplasmic localization were verified. Furthermore, the interaction between circNUP214 and miR-31 was confirmed, and the regulatory effect of circNUP214 on CD4 T cell proliferation was evaluated. In 31 pure AChR antibody-positive MG patients, circNUP214 expression was significantly elevated in PBMCs compared with healthy controls (HC). Elevated circNUP214 expression was also observed in CD4 T cells. Functionally, circNUP214 promoted CD4 T cell proliferation, while its knockdown suppressed this process. Mechanistically, circNUP214 directly bound miR-31 and upregulated NFAT5 via sponging miR-31. Rescue experiments in Jurkat cells further validated the circNUP214/miR-31/NFAT5 ceRNA regulatory axis. In conclusion, circNUP214 is highly expressed in PBMCs from 31 pure AChR antibody positive MG patients and is also elevated in CD4 T cells. It upregulates NFAT5 expression by sponging miR-31 to promote proliferation. These findings suggest that the circNUP214/miR-31/NFAT5 axis may contribute to aberrant CD4 T cell proliferation in MG. - Source: PubMed
Publication date: 2026/07/09
Xu FanfanKong XiaotongPeng ShanshanLi LifangTian WenqiCai HanluLi YichenLi YingNiu JingyanZhang NanZhang HuixueWang Lihua - Castration-resistant prostate cancer (CRPC) represents an aggressive stage of prostate cancer that develops following resistance to androgen deprivation therapy. Although androgen receptor (AR) signaling remains a central driver of disease progression, additional adaptive molecular mechanisms contribute to therapeutic resistance. Understanding the transcriptional programs underlying CRPC may facilitate the identification of novel biomarkers and therapeutic targets. - Source: PubMed
Publication date: 2026/06/25
Naeem Abdulghani AAbdulsamad Saud AHayat AteequllahNaeem AyeshaAlhazmi NadaFallata GhaithBokhari AnasAlharbi Abdulmajeed HAlkinani Kinani AAlshehri Abdullah MAldabbagh Khadijah M - Breast cancer remains a leading cause of cancer-related mortality worldwide, with triple-negative breast cancer (TNBC) representing a particularly aggressive subtype lacking targeted therapies. Inducing copper-mediated cell death stands as a significant therapeutic approach for tumors; however, research into non-coding RNA regulation of copper-mediated cell death in TNBC remains relatively scarce. This study analyses transcriptomic data from TNBC patients to identify long non-coding RNAs (lncRNAs) associated with copper-mediated cell death, aiming to uncover potential therapeutic targets. - Source: PubMed
Publication date: 2026/07/21
Chen JiChengFu XinghangGao XiaotanSun YingmingXiao JianChen WenxinWang HebingYang BinglinZhang MaoquanChen YongtianWen YanmeiLuo Huatian - Diabetic foot ulcer (DFU) lacks effective early diagnostic and therapeutic targets. - Source: PubMed
Publication date: 2026/07/21
Liu JinhuaCao LifengWang Xiaxia - Metabolic disorders represent a global health challenge requiring novel therapeutic strategies targeting the gut-liver axis. This study investigates the protective effects and mechanisms of lentinan, a bioactive polysaccharide from , against high-fat diet (HFD)-induced metabolic dysfunction. HFD-fed mice were treated with lentinan. Comprehensive phenotypic assessments, metagenome sequencing, hepatic transcriptomics, and correlation analyses were performed to elucidate mechanisms. Lentinan intervention significantly ameliorated dyslipidemia, hepatic steatosis, systemic inflammation, and intestinal barrier dysfunction in HFD-fed mice. Mechanistically, lentinan induced taxonomically selective gut microbiota remodeling, characterized by substantial enrichment of (positively correlated with hepatic expression) and reduction of (negatively correlated with and ), while paradoxically decreasing despite metabolic improvements. Hepatic transcriptomics revealed significant downregulation of glycerolipid metabolism and oxidative phosphorylation pathways, directly correlating with reduced lipid accumulation and improved serum biochemistry. Unlike conventional prebiotics, lentinan functions as a precision modulator of specific microbial metabolic functions, particularly L-arginine and uridine 5'-monophosphate (UMP) biosynthesis pathways, which interface with host inflammatory and lipid metabolism. These findings establish lentinan as a promising therapeutic candidate for metabolic syndrome management through coordinated gut microbiota-liver axis modulation, providing a conceptual framework for developing precision microbiome-targeted interventions. - Source: PubMed
Publication date: 2026/07/01
Cao DeminHuang LiweiZhang XinyueZhang XinyuZhao ZhiwenLong XidaiZhu XiaoyingLi Yulei